Hypertension, Obstructive Sleep Apnea
Conditions
Keywords
Continuous positive pressure ventilation, Blood pressure, Oxygen desaturation index, Endothelial dysfunction, Patient reported measurement
Brief summary
The aim of the present study is to compare the effects of different types of antihypertensive drugs (angiotensin II receptor blockers and long-acting calcium channel blockers) in patients with hypertension and obstructive sleep apnea who are not controlled well with their hypertension after continuous positive airway pressure therapy.
Detailed description
Obstructive sleep apnea (OSA) and hypertension have a significant interrelationship, and both disorders are well known risk factors for cardiovascular diseases (CVD). Treating them appropriately may improve the prognosis of the patients. Presently, continuous positive airway pressure (CPAP) therapy is the first-line therapy for OSA, and angiotensin II receptor blockers and long-acting calcium channel blockers for hypertension in Japan. Therefore, in the present study, we wanted to compare the effects of these different types of antihypertensive drugs on the control of blood pressure in patients with OSA whose hypertension is not controlled well after CPAP therapy.
Interventions
DRUGOlmesartan and Azelnidipine
1. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months 2. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months 3. Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months
Sponsors
Kyoto University, Graduate School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Apnea and hypopnea index of more than 20 /hr, and treated with CPAP * Uncontrolled hypertension (defined as systolic blood pressure of more than 130 mmHg or diastolic blood pressure of more than 80 mmHg
Exclusion criteria
* Cerebrovascular diseases, myocardial infarction, angina pectoris or heart failure within 6 months * Uncontrolled arrhythmia * Severe hepatic or renal disorders * Having poor prognosis disorders such as malignant disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure | Six months |
Secondary
| Measure | Time frame |
|---|---|
| Oxygen desaturation index | Six months |
| Pulse rate | Six months |
| Endothelial dysfunction | Six months |
| Sleep quality and sleepiness | Six months |
| Health-related quality of life | Six months |
Countries
Japan
Outcome results
None listed